Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease:  a case-control study

Saffalya Nayak; Pratima Kumari Sahu; Roma Rattan; Srikrushna Mahapatra; Debjyoti Mohapatra

doi:10.56782/pps.254

Data publikacji : 2024-09-26

Tom 22 Nr 3 (2024)

Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease: a case-control study

Saffalya Nayak

Pratima Kumari Sahu

Roma Rattan

Srikrushna Mahapatra

Debjyoti Mohapatra

DOI: https://doi.org/10.56782/pps.254

Abstrakt

Background: Fatty liver disease, particularly non-alcoholic fatty liver disease (NAFLD), affects around 25% of adults globally and up to 40% in developed countries. Often coexisting with type 2 diabetes mellitus (T2DM), NAFLD is linked to insulin resistance and metabolic syndrome. Irisin, a myokine induced by exercise, shows promise in enhancing insulin sensitivity, reducing hepatic steatosis, and improving metabolic health. Despite its potential, further research is needed to fully understand irisin's mechanisms and clinical implications in NAFLD and T2DM.

Objectives: This study investigates the irisin levels in T2DM patients with and without NAFLD and compares them with healthy controls.

Methods: A case-control study has been conducted involving 90 T2DM patients and 90 healthy controls, aged 30-55 years, recruited from SCB Medical College, Cuttack, between September 2021 and August 2022. Participants were screened for NAFLD using the Hepatosis Steatosis Index (HSI) and divided into four groups: T2DM with NAFLD, T2DM without NAFLD, controls with NAFLD, and controls without NAFLD. Serum irisin levels were measured using ELISA. Anthropometric data, physical activity, and various biochemical parameters were assessed and analyzed.

Results: The irisin levels were significantly lower in T2DM patients compared to healthy controls
(p = 0.001). Among T2DM patients, those with NAFLD had lower irisin levels than those without NAFLD, though not statistically significant (p = 0.299). Significant correlations were observed between irisin levels and insulin sensitivity markers such as HOMA-IR and QUICKI across different groups.

Conclusion: Lower irisin levels in T2DM patients, particularly those with NAFLD, highlight its potential role in the pathogenesis of metabolic disorders. Further research is needed to elucidate irisin's therapeutic implications in T2DM and NAFLD.

Podobne artykuły

Agnieszka Białek, Andrzej Tokarz, ŹRÓDŁA POKARMOWE ORAZ EFEKTY PROZDROWOTNE SPRZĘŻONYCH DIENÓW KWASU LINOLOWEGO (CLA) , Prospects in Pharmaceutical Sciences: Tom 7 Nr 1 (2009)
Sylwia Kraczkowska, Zofia Suchocka, Jan Pachecka, PODWYŻSZONE STĘŻENIE HOMOCYSTEINY WE KRWI JAKO WSKAŹNIK ZAGROŻENIA ZDROWIA , Prospects in Pharmaceutical Sciences: Tom 3 Nr 3 (2005)
Barbara Krzemińska, Gabriela Szewczyk, Cotoneaster horizontalis Decne. (Rosaceae) - the medicinal or just ornamental species? , Prospects in Pharmaceutical Sciences: Tom 22 Nr 2 (2024)
Arzu Birinci Yildirim, Ayca Cimen, Yavuz Baba, Arzu Turker, Natural- and in vitro-grown Filipendula ulmaria (L.) Maxim: evaluation of pharmaceutical potential (antibacterial, antioxidant and toxicity) and phenolic profiles , Prospects in Pharmaceutical Sciences: Tom 22 Nr 1 (2024)
Falah Saleh Mohammed, Mustafa Sevindik, İmran Uysal, Ali Erdem Sabik, Quercetin: derivatives, biosynthesis, biological activity, pharmacological and therapeutic effects , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Piotr Bojanowski, Piotr F. J. Lipiński, Paweł Czekała, Dariusz Plewczyński, LEKI WIELOCELOWE – NOWY PARADYGMAT W PROJEKTOWANIU LEKÓW , Prospects in Pharmaceutical Sciences: Tom 11 Nr 1 (2013)
Ewa Napiórkowska, Thiamine: overview of history of discovery, mechanism of action, role and deficiency , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Maciej Bara, Agata Janczak, Toxicity of anesthetic gases: exposure in operating rooms and influence on the environment. , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Kinga Grużewska-Piotrowska, Agnieszka Grużewska, Ból głowy z nadużywania leków przeciwbólowych – przegląd aktualnej literatury , Prospects in Pharmaceutical Sciences: Tom 21 Nr 3 (2023)
Maciej Stępień, Stanisław Anczyk, Leczenie ukierunkowane na cytokiny w łysieniu plackowatym - nowe możliwości? , Prospects in Pharmaceutical Sciences: Tom 21 Nr 2 (2023)

<< < 1 2 3 4 5 6 7 > >>

Możesz również Rozpocznij zaawansowane wyszukiwanie podobieństw dla tego artykułu.

Szczegóły

Bibliografia

Statystyki

Autorzy

Pobierz pliki

PDF (English)

Zasady cytowania

Nayak, S., Sahu, P. K., Roma Rattan, Mahapatra, S., & Mohapatra, D. (2024). Irisin levels in type 2 diabetes mellitus with and without non-alcoholic fatty liver disease: a case-control study. Prospects in Pharmaceutical Sciences, 22(3), 210–218. https://doi.org/10.56782/pps.254

Wskaźniki altmetryczne

Cited by / Share

Licencja

Utwór dostępny jest na licencji Creative Commons Uznanie autorstwa 4.0 Międzynarodowe.

Bibliografia

Dharmalingam, M.; Yamasandhi, P.G. Nonalcoholic fatty liver disease and Type 2 diabetes mellitus. Indian J. Endocrinol. Metab. 2018, 22, Art. No: 421. DOI: 10.4103/ijem.IJEM_585_17 DOI: https://doi.org/10.4103/ijem.IJEM_585_17

Boström, P.; Wu, J.; Jedrychowski, M.P.; Korde, A.; Ye, L.; Lo, J.C.; et al. A PGC1α-dependent myokine that drives browning of white fat and thermogenesis. Nature 2011, 481, 463–468. DOI: 10.1038/nature10777 DOI: https://doi.org/10.1038/nature10777

Zhang, T.; Yi, Q.; Huang, W.; Feng, J.; Liu, H. New insights into the roles of Irisin in diabetic cardiomyopathy and vascular diseases. Biomed. Pharmacother. 2024, 175, Art. No: 116631. DOI: 10.1016/j.biopha.2024.116631 DOI: https://doi.org/10.1016/j.biopha.2024.116631

Hu, J.; Ke, Y.; Wu, F.; Liu, S.; Ji, C.; Zhu, X.; et al. Circulating Irisin Levels in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Gastroenterol. Res. Pract. 2020, 2020, Art. No: 8818191. DOI: 10.1155/2020/8818191 DOI: https://doi.org/10.1155/2020/8818191

Hou, N.; Liu, Y.; Han, F.; et al. Irisin improves perivascular adipose tissue dysfunction via regulation of the heme oxygenase-1/adiponectin axis in diet-induced obese mice. J. Mol. Cell. Cardiol. 2016, 99, 188–196. DOI: 10.1016/j.yjmcc.2016.09.005 DOI: https://doi.org/10.1016/j.yjmcc.2016.09.005

Zhang, Y.; Li, R.; Meng, Y.; et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014, 63, 514–525. DOI: 10.2337/db13-1106 DOI: https://doi.org/10.2337/db13-1106

Wang, C.; Wang, L.; Li, W.; et al. Irisin has no effect on lipolysis in 3T3-L1 adipocytes or fatty acid metabolism in HepG2 hepatocytes. Endocrine 2015, 49, 90–96. DOI: 10.1007/s12020-014-0458-9 DOI: https://doi.org/10.1007/s12020-014-0458-9

Zhang, H.J.; Zhang, X.F.; Ma, Z.M.; Pan, L.L.; Chen, Z.; et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J. Hepatol. 2013, 59, 557–562. DOI: 10.1016/j.jhep.2013.04.030 DOI: https://doi.org/10.1016/j.jhep.2013.04.030

Polyzos, S.A.; Kountouras, J.; Anastasilakis, A.D.; Geladari, E.V.; Mantzoros, C.S. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014, 63, 207–217. DOI: 10.1016/j.metabol.2013.09.013

World Health Organization. Diagnosis and management of type 2 diabetes (HEARTS-D). Geneva: World Health Organization; 2020. WHO/UCN/NCD/20.1. Available online: https://www.who.int/publications/i/item/9789240062147 (accessed on 9 August 2019).

World Health Organization. Global Physical Activity Questionnaire (GPAQ) Analysis Guide. Geneva: World Health Organization; 2016. Available online: https:// www.who.int/publications/m/item/global-physical-activity-questionnaire (accessed on 9 August 2019).

Kosmalski, M.; Drzewoski, J.; Szymczak-Pajor, I.; Zieleniak, A.; Mikołajczyk-Solińska, M.; Kasznicki, J.; Śliwińska, A. Irisin is related to non-alcoholic fatty liver disease (NAFLD). Biomedicines 2022, 10, Art. No: 2253. DOI: 10.3390/biomedicines10092253 DOI: https://doi.org/10.3390/biomedicines10092253

Bazick, J.; Donithan, M.; Neuschwander Tetri, B.A.; Kleiner, D.; Brunt, E.M.; Wilson, L.; et al. Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: Guidelines for referral in NAFLD. Diabetes Care 2015, 38, 1347–1355. DOI: https://doi.org/10.2337/dc14-1239

Lee, J.H.; Kim, D.; Kim, H.J.; et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig. Liver Dis. 2010, 42, 503–508. DOI: 10.1016/j.dld.2009.08.002 DOI: https://doi.org/10.1016/j.dld.2009.08.002

Jiang, Z.G.; de Boer, I.H.; Mackey, R.H.; et al. Associations of insulin resistance, inflammation and liver synthetic function with very low-density finlipoprotein: The Cardiovascular Health Study. Metabolism 2016, 65, 92–99. DOI: 10.1016/j.metabol.2015.10.017 DOI: https://doi.org/10.1016/j.metabol.2015.10.017

Shanaki, M.; Moradi, N.; Emamgholipour, S.; Fadaei, R.; Poustchi, H. Lower circulating irisin is associated with nonalcoholic fatty liver disease and type 2 diabetes. Diabetes Metab. Syndr. 2017, 11, S467–S472. DOI: https://doi.org/10.1016/j.dsx.2017.03.037

Choi, E.S.; Kim, M.K.; Song, M.K.; et al. Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees. PLoS One 2014, 9, Art. No: e110680. DOI: https://doi.org/10.1371/journal.pone.0110680

Mahmoodnia, L.; Sadoughi, M.; Ahmadi, A.; Kafeshani, M. Relationship between serum irisin, glycemic indices, and renal function in type 2 diabetic patients. J. Renal Inj. Prev. 2017, 6, 88–92. DOI: 10.15171/jrip.2017.17 DOI: https://doi.org/10.15171/jrip.2017.17

Wen, M.S.; Wang, C.Y.; Lin, S.L.; Hung, K.C. Decrease in irisin in patients with chronic kidney disease. PLoS One 2013, 8, Art. No: e64025. DOI: https://doi.org/10.1371/journal.pone.0064025

Liu, J.J.; Liu, S.; Wong, M.D.; Tan, C.S.; Tavintharan, S.; Sum, C.F.; et al. Relationship between circulating irisin, renal function and body composition in type 2 diabetes. J. Diabetes Complicat. 2014, 28, 208–213. DOI: 10.1016/j.jdiacomp.2013.09.011 DOI: https://doi.org/10.1016/j.jdiacomp.2013.09.011

Ma, Y.; Wu, X.; Liu, X.; et al. Expression of irisin in liver tissue of patients with nonalcoholic fatty liver disease. J. Zhengzhou Univ. 2016, 51, 517–520.

Park, K.H.; Zaichenko, L.; Brinkoetter, M.; et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J. Clin. Endocrinol. Metab. 2013, 98, 4899–4907. DOI: https://doi.org/10.1210/jc.2013-2373

Saffalya Nayak

nayaksaffalya@gmail.com

Afiliacja:

a:1:{s:5:"en_US";s:33:"SCB Medical College and Hospital ";} India

Pratima Kumari Sahu

drpratimasahu@gmail.com

Afiliacja:

SCB Medical College and Hospital India

Biogram

Head of The Department,SCB Medical College and Hospital,Cuttack,Odisha,India

Roma Rattan

drrattanroma@gmail.com

Afiliacja:

Directorate of Medical Education,Odisha India

Biogram

Joint DMET

Srikrushna Mahapatra

srikrushna.mahapatra@gmail.com

Afiliacja:

Kalinga Institute of Medical Sciences,Bhubaneswar,Odisha India

Biogram

Head of the Department,Biochemistry

Debjyoti Mohapatra

drdebjyoti@gmail.com

Afiliacja:

SJ Medical College and Hospital,Puri,Odisha,India India

Biogram

Assistant Professor